RESUMO
INTRODUCTION: MicroRNAs are regulatory non-coding RNAs, with their outstanding regulatory mechanism, that make them potential biomarker for disease detection and therapeutics. They play an important role in pathological state, such as cancer by acting as oncogenic microRNAs and tumor suppressor microRNAs. The expression of microRNA-206, microRNA-4477a, microRNA-4795-5p, microR-4796-3p, microRNA-451b, and microRNA-4311 has proven to be deregulated in different cancer studies. However, no comprehensive study has been reported yet regarding their role in glioma patients. AIM: The present study is designed to examine the expression profiling of microRNAs, such as microRNA-206, microRNA-4477a, microRNA-4795-5p, microR-4796-3p, microRNA-451b, and microRNA-4311 in glioma patients. Furthermore, the expression deregulation of selected microRNAs was correlated with oxidative stress and proliferation rate in glioma patients. METHODS: For this purpose, 153 glioma tissue samples and 200 brain tissues from epilepsy patients (taken as controls) were collected in the present study. Expression analysis of selected microRNAs was carried out on collected samples using real-time PCR (qPCR). Oxidative stress and proliferation rate were measured by estimation of 8OXOG level and Ki-67 using the ELISA and IHC. RESULTS: Our results showed significant deregulation of microRNA-206 (p < 0.0001), microRNA-4477a (p < 0.01), microRNA-4311 (p < 0.0001), microRNA-4795-5p (p < 0.0001), microRNA-4796-3p (p < 0.0001), and microRNA-451b (p < 0.0001) in glioma patients compared to controls. However, significant upregulation of 8OXOG level (p < 0.0001) and Ki-67 (p < 0.0001) was observed in glioma patients compared to controls. Kaplan-Meier analysis showed that deregulated expression of selected microRNAs was associated with significant decrease in survival of glioma patients. CONCLUSIONS: Our results demonstrated significant deregulation of selected microRNAs in glioma patients. This deregulated expression was found associated with significant increased risk of glioma and could be further developed as effective prognostic biomarker and therapeutic tool in said disease.